欧州機関は,重度のCOVID-19呼吸器障害に対する新たな治療の承認を勧告する. European agency recommends approval for new treatment for severe COVID-19 respiratory distress.

欧州医薬品庁の委員会は InflaRx'GOHIBIC (vilobelimab)の承認を提案している。 The European Medicines Agency's committee has recommended approval for InflaRx's GOHIBIC (vilobelimab) to treat adults with severe SARS-CoV-2-induced respiratory distress syndrome under exceptional circumstances. Viobelimab は , コルチコステロイドや機械的な通気装置の患者のためのものです。 Vilobelimab is intended for patients on corticosteroids and mechanical ventilation. 積極的な勧告は,患者の成果を改善し死亡率を下げる可能性に基づいており,約2か月以内に最終承認を受けるものと見なされる. The positive recommendation is based on its potential to improve patient outcomes and reduce mortality, and it is expected to receive final approval within about two months.

November 15, 2024

5 記事